Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ganitumab (Primary) ; Rilotumumab (Primary) ; Carboplatin; Cisplatin; Etoposide
Indications Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms QUILT-2.013
Sponsors Amgen; NantCell

03 Jun 2014 Pharmacokinetic substudy results for rilotumumab and placebo arms presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
29 Oct 2013 Primary endpoint 'Overall-survival-duration' has not been met.
08 Mar 2013 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com